Zentalis Pharmaceuticals announces management participation in three upcoming investor conferences showcasing their WEE1 inhibitor research.
Quiver AI Summary
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer and other tumors, announced that its management will participate in several upcoming investor conferences: the Wells Fargo Healthcare Conference on September 4, the H.C. Wainwright Global Investment Conference on September 8, and the Morgan Stanley Global Healthcare Conference on September 9. The company's lead product, azenosertib (ZN-c3), is being evaluated in clinical trials for its potential as a first-in-class treatment for Cyclin E1+ platinum-resistant ovarian cancer and has shown promise in terms of safety and anti-tumor activity. Live webcasts and archived recordings of the presentations will be accessible on the company's website. For more details, Zentalis can be followed on LinkedIn and its website.
Potential Positives
- Participation in multiple prominent investor conferences enhances the company's visibility and engagement with potential investors.
- The development of azenosertib as a potentially first-in-class WEE1 inhibitor positions Zentalis as an innovator in addressing ovarian cancer and other tumor types.
- The positive outcomes of azenosertib in clinical trials indicate promising anti-tumor activity and patient tolerance, which may attract further investment and support for ongoing research.
- The company’s efforts to explore additional research opportunities beyond ovarian cancer demonstrate strategic growth potential and adaptability in its drug development portfolio.
Potential Negatives
- None
FAQ
What is Zentalis Pharmaceuticals known for?
Zentalis Pharmaceuticals is known for developing a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumors.
When will Zentalis participate in investor conferences?
Zentalis will participate in three investor conferences from September 4 to September 9, 2025.
Where can I find webcast information for Zentalis events?
Live webcasts and archived recordings of Zentalis events will be available on their website under the "Events & Presentations" tab.
What is azenosertib?
Azenosertib (ZN-c3) is a WEE1 inhibitor being evaluated in clinical trials for various tumors, particularly platinum-resistant ovarian cancer.
How has azenosertib performed in clinical trials?
Azenosertib has been well tolerated in trials and has shown anti-tumor activity across multiple tumor types.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZNTL Insider Trading Activity
$ZNTL insiders have traded $ZNTL stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZNTL stock by insiders over the last 6 months:
- SCOTT DUNSETH MYERS purchased 21,000 shares for an estimated $29,372
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZNTL Hedge Fund Activity
We have seen 58 institutional investors add shares of $ZNTL stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVENTIDE ASSET MANAGEMENT, LLC removed 4,475,054 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $7,115,335
- BLACKROCK, INC. removed 2,487,750 shares (-58.8%) from their portfolio in Q2 2025, for an estimated $2,885,790
- MPM BIOIMPACT LLC removed 1,106,851 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,759,893
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC removed 1,050,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,669,500
- STATE STREET CORP removed 1,047,995 shares (-79.4%) from their portfolio in Q2 2025, for an estimated $1,215,674
- BALYASNY ASSET MANAGEMENT L.P. added 970,862 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,126,199
- GEODE CAPITAL MANAGEMENT, LLC removed 737,502 shares (-54.4%) from their portfolio in Q2 2025, for an estimated $855,502
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZNTL Analyst Ratings
Wall Street analysts have issued reports on $ZNTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/15/2025
To track analyst ratings and price targets for $ZNTL, check out Quiver Quantitative's $ZNTL forecast page.
$ZNTL Price Targets
Multiple analysts have issued price targets for $ZNTL recently. We have seen 4 analysts offer price targets for $ZNTL in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $5.0 on 08/07/2025
- Robert Driscoll from Wedbush set a target price of $4.0 on 05/15/2025
- Andres Maldonado from HC Wainwright & Co. set a target price of $10.0 on 05/15/2025
Full Release
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
-
2025 Wells Fargo Healthcare Conference, Boston, MA.
- Fireside chat, September 4, 2025, 10:15 a.m. ET.
-
H.C. Wainwright 27th Annual Global Investment Conference, New York, NY.
- Company presentation, September 8, 2025, 2:30 p.m. ET.
-
Morgan Stanley 23rd Annual Global Healthcare Conference, New York, NY.
- Fireside chat, September 9, 2025, 7:00 a.m. ET.
Access to live webcasts of the events, as well as archived recordings, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website .
About Zentalis Pharmaceuticals
Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN- c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum- resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS ® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
[email protected]
